Comparative study of the metabolic and anthropometric profile of patients with polycystic ovary syndrome under treatment with oral contraceptives containing drospirenone or cyproterone
Keywords:Polycystic ovary syndrome; Metabolic syndrome; Oral contraceptive.
Polycystic Ovary Syndrome (PCOS) is a heterogeneous endocrine dysfunction characterized by oligoamenorrhea and hyperandrogenism. It is associated with comorbidities such as insulin resistance, hyperlipidemia, cardiovascular diseases, cosmetic problems and infertility. Analyse and compare possible impacts on the anthropometric, metabolic and cardiovascular profiles of patients with PCOS before and after 06 months of treatment with combined oral contraceptives (COC) containing Ethinylestradiol (EE) 0.035mg + Cyproterone 2mg or EE 0.03mg + Drospirenone 3mg. Observational, prospective and analytical study, with quantitative approach, approved by the REC of HU-UFPI (number 2.568.977), accomplished between August 2018-June 2019. Women aged 18 to 40 years with a confirmed diagnosis for PCOS were selected and divided into two homogeneous groups to use the following combinations for 06 months: Group 1 (EE + Cyproterone) and Group 2 (EE + Drospirenone). Statistical t-Student and Mann-Whitney U tests were used for data analysis, with a 5% significance level. Anthropometric and metabolic data of the 16 selected participants were analyzed before and after 6 months of COC therapy. There was a statistically significant reduction in BMI in group 2 and a significant increase in HDL and Total Cholesterol in group 1. After 06 months of using these COCs, it was observed: improvement in Total Cholesterol and HDL with EE + Cyproterone; reduction in BMI with EE + Drospirenone; absence of additional risk in the metabolic, anthropometric and cardiovascular profile; no clinical superiority in the metabolic risk of one hormonal combination over the other in patients with PCOS.
Abeso. (2009). Associação Brasileira para o estudo da obesidade e da Síndrome Metabólica. ABESO 3ª ed. São Paulo, 2010.
Brandão, A.P. et al. (2005). I Diretriz brasileira de diagnóstico e tratamento da síndrome metabólica. Arq Bras Cardiol, 84, 1-28
Aydin, K., Cinar, N., Aksoy, D. Y., Bozdag, G., & Yildiz, B. O. (2013). Body composition in lean women with polycystic ovary syndrome: effect of ethinyl estradiol and drospirenone combination. Contraception, 87(3), 358-362.
Brasil. Ministério da Saúde. Consulta Pública nº 33, de 26 de agosto de 2010. Brasília: Secretaria de Atenção à Saúde, 2010.
Disponível em: http://bvsms.saude.gov.br/bvs/saudelegis/sas/2010/cop0033_26_08_2010.html. Acesso em: 17. out. 2015.
Christ, J. P., Willis, A. D., Brooks, E. D., Brink, H. V., Jarrett, B. Y., Pierson, R. A., ... & Lujan, M. E. (2014). Follicle number, not assessments of the ovarian stroma, represents the best ultrasonographic marker of polycystic ovary syndrome. Fertility and sterility, 101(1), 280-287.
Finotti, M. Repercussões não reprodutivas da SOP na saúde da mulher. (20130. O que e como avaliar? In: CONGRESSO DE GINECOLOGIA E OBSTETRÍCIA DO DISTRITO FEDERAL, 46. Brasília: SGOB.
Gallo, M. F., Lopez, L. M., Grimes, D. A., Carayon, F., Schulz, K. F., & Helmerhorst, F. M. (2014). Combination contraceptives: effects on weight. Cochrane Database of Systematic Reviews, (1).
Glintborg, D. (2016). Endocrine and metabolic characteristics in polycystic ovary syndrome. Danish Medical Journal. Apr;63(4):B5232.
Guastella, E., Longo, R. A., & Carmina, E. (2010). Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes. Fertility and sterility, 94(6), 2197-2201.
Hong, S. H., Sung, Y. A., Hong, Y. S., Jeong, K., Chung, H., & Lee, H. (2017). Polycystic ovary morphology is associated with insulin resistance in women with polycystic ovary syndrome. Clinical endocrinology, 87(4), 375-380.
Jeanes, Y. M., & Reeves, S. (2017). Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges. Nutrition research reviews, 30(1), 97-105.
Lopes, I. M. R. S., Baracat, M. C. P., Simões, M. J., Simões, R. S., Baracat, E. C., & Soares Jr, J. M. (2011). Endométrio na janela de implantação em mulheres com síndrome dos ovários policísticos. Revista da Associação Médica Brasileira, 57(6), 702-709.
Lopez, L. M., Grimes, D. A., & Schulz, K. F. (2014). Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database of Systematic Reviews, (4).
Medeiros, SF (2017). Riscos, tamanho dos benefícios e implicações clínicas do uso de anticoncepcionais orais combinados em mulheres com síndrome dos ovários policísticos. Reproductive Biology and Endocrinology , 15 (1), 1-17.
Melo, A. S., Dos Reis, R. M., Ferriani, R. A., & Vieira, C. S. (2017). Hormonal contraception in women with polycystic ovary syndrome: choices, challenges, and noncontraceptive benefits. Open access journal of contraception, 8, 13.
How to Cite
Copyright (c) 2021 Beatriz Mendes de Araujo; Morgana Pinheiro Albuquerque; Ione Maria Ribeiro Soares Lopes
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.